The United States faces unprecedented risks to national security in the 21st century posed by the clear and growing danger of bioterrorism or a destabilizing infectious disease pandemic. Our nation’s vulnerability to biothreats is so severe simply because most of the vaccines and medicines that will be needed to protect our citizens during and after such events do not now exist, and will likely require several years and several hundred million dollars each to successfully develop and produce.
The Alliance is a collaboration among pharmaceutical and biotechnology companies that are working in the public interest to improve prevention and treatment of severe infectious diseases — particularly those diseases that present global security challenges. Alliance member companies believe that innovations created in the biodefense space can inform and accelerate drug and vaccine development in many critical areas. The Alliance supports a long-term national security vision for achieving and sustaining defenses against a range of infectious disease threats that present national security challenges.